Human Microbiome Market

Industry Outlook

The human microbiome market is set to reach US$ 1,990.5 Mn by 2026 from US$ 840.1 Mn in 2017 at a compound annual growth rate (CAGR) of 10.1% during the forecast period from 2018 to 2026. According to the research findings of World Health Organization (WHO), the burden associated with non-communicable diseases is set increase to 57% by 2020. The mortality rate related to chronic diseases will be more pronounced in the developing regions in comparison to the developed regions.

The major factors related to gastrointestinal disorders related to dietary problems are stress, low dietary intake, taking antacids frequently, sedentary lifestyle and craving for junk food etc. As mentioned in Lancet Research Journal 2016, chronic diseases such as diabetes, cardiovascular diseases, ulcerative colitis and even cancer can be prevented by maintaining healthy lifestyle and healthy dietary intake rich in probiotics, prebiotics and micronutrients.

Market Synopsis

Prebiotics and probiotics are the largest product segment owing to its therapeutic efficacy

Probiotics are healthy microorganism which aid in fighting against impending gastrointestinal diseases. They have been found beneficial in building the immune defense mechanism. The rich source of probiotics are dairy products especially yoghurt. Prebiotics are basically food for probiotics, they are fiber in nature which are consumed by probiotics in the intestinal tract releasing essential short chain fatty acids, essential amino acids etc. The rich sources of prebiotics are chicory root, Jerusalem artichoke, dandelion greens, garlic, leeks, onions etc. Probiotics and prebiotics are dominating the market due to rising prevalence of gastrointestinal disorders and increasing public health awareness. Supplements are gaining prominence on account of developing nutraceutical industry and growing importance of micronutrients in daily dietary intake.

Growing importance of gut microflora in diagnosing gastrointestinal disorders propel the human microbiome market

In the last two decades diligent research activities conducted in the nutraceutical and medical food industries has proven the therapeutic importance of human microbiota. There are millions of microbial gut flora which are either symbiotic or pathogenic in nature are present in the human intestine. Symbionts are very helpful in the digestion and absorption of nutrients, synthesis of certain amino acids and aid in building the immune system. Probiotics mimic these helpful microbial gut flora to maintain proper homeostasis of the human health. Researchers throughout the globe have concluded that microbes finding safe harbor in the human gut habitat can be harnessed to detect diseases ranging from acute infection to chronic inflammatory conditions.

Rising prevalence of gastrointestinal disorders and established healthcare R&D segment drives the North America market

In the present scenario North America is the clear leader in human microbiome market on account of the rising prevalence of gastrointestinal disorders and unhealthy eating and sedentary lifestyle. C.difficile infection, enterocolitis and diarrhea are the most occurring infectious intestinal diseases in North America. There is burgeoning requirement of probiotics to balance the microbial gut flora. In Europe the human microbiome market is driven by establishment of well-developed nutraceutical industry pioneering in prebiotics, probiotics and medical food. Asia Pacific is set to register excellent growth during the forecast period owing to key parameters such as increasing urbanization causing slums with poor civic amenities and lack of sanitation leading to intestinal diseases. In South East Asia infants suffer severely with cholera and diarrhea due to polluted drinking water. Asia Pacific serves as a lucrative market for medical food and supplement for the infants.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Qualitative and quantitative market analysis were performed to determine the market estimation and compounded annual growth rate (CAGR). The market segment comprises of by product, application and geography.

Market estimation and compounded annual growth rate were determined for human microbiome market by performing in depth analysis of the organic and inorganic growth strategies. Latest technological developments and recent trends prevailing in the human microbiome market are discussed thoroughly in the report. Patient compliance and their buying patterns related to supplements and medicinal food are thoroughly discussed in the report. Competitive landscape is covered to study the existing competitive nature among the major players of human microbiome market. Diverse varieties of food products are covered in the product portfolio segment. The major players providing human microbiomes are DuPont, Enterome Bioscience, Osel, Inc., Second Genome, Inc., Seres Therapeutics, Synthetic Biologics, Inc., Synlogic, Inc., Vedanta Biosciences, Inc., Vithera Pharmaceuticals and Yakult Honsha Co., Ltd.

Key questions answered in this report

• What are the organic and inorganic growth strategies applied to perform the market assessment for human microbiome market?
• Who are the leading human microbiome products providers?
• What are the latest technological developments taking place in the human microbiome market?
• What is the competitive scenario among the human microbiome providers?
• Which is the leading and fastest growing products segment in the human microbiome market?
• Which is the leading and fastest growing application segment in the human microbiome market?
• Which is the leading and fastest growing regional segment in the human microbiome market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global HM Market Portraiture
2.2. Global HM Market, by Product, 2017 (US$ Mn)
2.3. Global HM Market, by Application, 2017 (US$ Mn)
2.4. Global HM Market, by Geography, 2017 (US$ Mn)

Chapter 3. Human Microbiome (HM) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global HM Market, by Key Players, 2017

Chapter 4. Global Human Microbiome (HM) Market, by Product
4.1. Overview
4.2. Probiotics
4.3. Prebiotics
4.4. Medical Foods
4.5. Supplements
4.6. Others

Chapter 5. Global Human Microbiome (HM) Market, by Application
5.1. Overview
5.2. Diagnostics
5.3. Therapeutics

Chapter 6. Global Human Microbiome (HM) Market, by Geography
6.1. Overview
6.2. North America HM Market Analysis, 2016 – 2026
6.2.1. North America HM Market, by Product, 2016 – 2026 (US$ Mn)
6.2.2. North America HM Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America HM Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe HM Market Analysis, 2016 – 2026
6.3.1. Europe HM Market, by Product, 2016 – 2026 (US$ Mn)
6.3.2. Europe HM Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific HM Market Analysis, 2016 – 2026
6.4.1. Asia Pacific HM Market, by Product, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific HM Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America HM Market Analysis, 2016 – 2026
6.5.1. Latin America HM Market, by Product, 2016 – 2026 (US$ Mn)
6.5.2. Latin America HM Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa HM Market Analysis, 2016 – 2026
6.6.1. MEA HM Market, by Product, 2016 – 2026 (US$ Mn)
6.6.2. MEA HM Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. DuPont
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Enterome Bioscience
7.3. Osel, Inc.
7.4. Second Genome, Inc.
7.5. Seres Therapeutics
7.6. Synthetic Biologics, Inc.
7.7. Synlogic, Inc.
7.8. Vedanta Biosciences, Inc.
7.9. Vithera Pharmaceuticals
7.10. Yakult Honsha Co., Ltd.

List of Figures

FIG. 1 Human Microbiome (HM) Market: Research Methodology
FIG. 2 HM Market Segmentation
FIG. 3 Global HM Market, by Product, 2017 (US$ Mn)
FIG. 4 Global HM Market, by Applications, 2017 (US$ Mn)
FIG. 5 Global HM Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global HM Market, by Key Players, 2017
FIG. 8 Global Probiotics Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 9 Global Prebiotics Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 10 Global Medical Foods Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 11 Global Supplements Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 12 Global Other Products Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 13 Global Diagnostics Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 14 Global Therapeutics Market for Human Microbiome, 2016 – 2026 (US$ Mn)
FIG. 15 U.S. HM Market, 2016 – 2026 (US$ Mn)
FIG. 16 Canada HM Market, 2016 – 2026 (US$ Mn)
FIG. 17 U.K. HM Market, 2016 – 2026 (US$ Mn)
FIG. 18 Germany HM Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Europe HM Market, 2016 – 2026 (US$ Mn)
FIG. 20 China HM Market, 2016 – 2026 (US$ Mn)
FIG. 21 Japan HM Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Asia Pacific HM Market, 2016 – 2026 (US$ Mn)
FIG. 23 Brazil HM Market, 2016 – 2026 (US$ Mn)
FIG. 24 Mexico HM Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of Latin America HM Market, 2016 – 2026 (US$ Mn)
FIG. 26 GCC HM Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest of MEA HM Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Human Microbiome (HM) Market Portraiture
TABLE 2 Global HM Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 3 Global HM Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 4 Global HM Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America HM Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 6 North America HM Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 7 North America HM Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe HM Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 9 Europe HM Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 10 Europe HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific HM Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific HM Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America HM Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America HM Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa HM Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East and Africa HM Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East and Africa HM Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 DuPont: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Enterome Bioscience: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Osel, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Second Genome, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Seres Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Synthetic Biologics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Synlogic, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Vedanta Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Vithera Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Yakult Honsha Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)